Member Info for Antha

Does anyone know the actual final cost of BPC acquiring the Cerp assets?
We know the reason why was to have a Plan B if P1 wasn't commercial which is where we are now BUT what if we never had the Cerp assets therefore saving £M's in acquiring them, surely we could have used that money to have kept drilling to TD which would then have had a greater chance of finding commercial oil, I know that means there was a 70% chance of going bust but to fall at the last hurdle though lack of funds is just bad planning unless of course a farm out was the plan all along.

GRH "whoever gets the max ticks and is acceptable to me", always a red flag when there's a bb self appointed guru.

That's the difference, this WASN'T a Covid test kit company, it only started getting in to test kits late last year and in fact in the rns it states "Revenue from this product portfolio has helped IDS deliver the strong performance seen in H2 FY21" so they are indeed making money from their Covid testing portfolio.

This share is a medium to long term hold and always has been, I like it because it's stable with good steady growth even during the pandemic, I agree with the previous post in that at some point IDH will probably be taken over.

Nice steady growth but the important bit in the rns is..

"IDS now has a comprehensive portfolio of COVID-19 tests available - ranging across fully automated IgG and IgM antibody tests, manual ELISA tests and distribution rights for a variety of rapid antibody and antigen tests. Revenue from this product portfolio has helped IDS deliver the strong performance seen in H2 FY21.
As explained in our most recent Interim Report, the focus of health authorities is currently on antigen testing - to test for an active infection of SARS CoV-2. IDS is working with our partners to gain approval for more convenient antigen tests, which are not reliant on the unpleasant nasopharyngeal swab sample collection method, to the European market. We will be well positioned to secure a share of this market assuming approval of these products is forthcoming.
In terms of antibody testing, with the progression of the vaccine rollouts globally, public health studies into antibody levels in the population should increase to enable the success of this program to be measured. This is likely to drive additional demand for antibody testing, and because a fully automated solution such as that offered by IDS provides better accuracy than rapid tests, and better laboratory efficiency than manual ELISA based tests, IDS is well positioned to win a share of the laboratory business for these tests."

As stated by many it's either a Farm Out or Dilution, one or the other and until the bod releases any news then it's just guess work.

No one's as bad as the idiot Graham Lumsden who managed to completely destroy a perfectly good company through his ineptitude, a 95% drop in the sp in one day must be a record.

Always a good sign when a lot of derampers turn up, hopefully break 0.7p by the end of tomorrow.

doug "7000bod, maintaining 75% profit margin, WTI of $62, forward PE 33 & 17B OS & from your 2 charts, then giving an sp c.20p...??"

SP @20p would make a lot of us multi millionaires, maybe many years down the road but short term I would be happy with 7p.

Good post and I agree it would be possible IF everything went to plan with all drills being a success and poo staying high, unfortunately 3 years is a long time and lgo/cerp/bpc history say's otherwise, a farm out would of course change the situation instantly.

Tiburn "If no Major farm out in 3 months, then so be it - its self fund P#2 and the longer road"
Unless the P1 drill results are really good there's no way BPC could self fund a P2 drill within the required 3 years, pi's certainly won't put up with more dilution.

Yep normally middle of April, if the numbers are good then a short term spike to about 300p before inevitably falling back. One thing this company must improve on is a more regular news flow such as sales etc.

Both those are more common than you think on wildcat drills, the bod's complete failure is not foreseeing, planning and providing contingency funding in the eventuality they might happen, unfortunately for us they did happen and the sp dived accordingly.
One can only go by what is released via rns and apparently we were fully funded when obviously we weren't.
For the record I still think there is hope for the company, just not in the Bahamas.

If you were told before the P1 drill that (a) it was not fully funded and (b) we would not drill to TD, would you honestly have invested in the first place, I know I certainly would not have done.

Excellent post AM and welcome to the forum.

GG, my personal opinion is if there's no farm out there will almost certainly be a placement and not at a premium either, I will double my holding once one of those happens, but long term this share will multi bag we just need patience.

mannan - "this will rise again see 88e .came down as low as 0.32 .now near 3p .but they have no oil at all"
Yep it's all about sentiment, unfortunately Potter killed it for us pre P1 drill but our time to shine will come eventually.

Tiburn - "In all matters all the arguments comes to one thing - farm out required - or the new 3 year licence will just default to drop and never get to drill."
Absolutely right, however I think the chances of a farm out are less than 50% and probably dropping each day.
88E's current rise is exactly what most pi's were hoping for prior to the P1 drill, unfortunately problems with the drill, Potter not telling the truth about being fully funded (again) and the absolute woeful LO funding deal means everyone is now trapped until the bod collectively pull their finger out and start doing things right.

The main points:

The Test has received the US Food and Drug Administration's ("FDA") Emergency Use Authorisation ("EUA"). As a result, IDS is now able to sell the Test to laboratories in the USA for clinical testing purposes.

The Test has been developed for identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection. The Test exceeds the FDA`s sensitivity and specificity requirements for laboratory run serology tests. It provides 100% Positive Percent Agreement after 7 days of diagnosis by RT-PCR and 99.6% Negative Percent Agreement for pre-endemic samples.

The Test does not cross react with other strains of coronavirus, significantly reducing the risk of false positives.

All steps of the Test are automated with no manual reagent preparation required, ensuring a high daily throughput. Test results are available within 25 minutes and can be run on any of the IDS-iSYS analysers which are already installed in numerous hospitals and laboratories in the USA. Each iSYS is capable of running over 10,000 tests per month.

Tests will be available for sale at the end of April. By providing our customers with this fully automated and flexible laboratory solution, IDS has the potential to increase our testing volumes in the US market, as well as attract new customers to the IDS platform.

All sales figures including Covid tests will be in the update released in two weeks time, that's when the sp should rise significantly.